Ceritinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ceritinib: From ALK-Positive Non-Small Cell Lung Cancer to Gingival Fibromatosis
One-Sentence Summary
Ceritinib is a second-generation ALK tyrosine kinase inhibitor whose approved use — based on the trial and review literature returned in this evidence pack — is ALK-rearranged non-small cell lung cancer (NSCLC); the drug's own structured original-indication field is empty in this pack (data gap). The TxGNN model's top prediction for this drug is Gingival Fibromatosis, but this prediction has zero clinical trials and zero literature support and no known mechanistic link to the ALK pathway — it is a model-score-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | ALK-positive (ALK-rearranged) non-small cell lung cancer — inferred from literature within this evidence pack (e.g., ASCEND-4, "Ceritinib: first global approval"); not available from the structured taiwan_regulatory/original_indications fields (data gap) |
| Predicted New Indication | Gingival Fibromatosis (Fibromatosis, Gingival) |
| TxGNN Prediction Score | 99.86% (rank 2020 among all candidates) |
| Evidence Level | L5 |
| Taiwan Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the structured original_moa field (data gap, DG002). Based on the literature captured elsewhere in this evidence pack, ceritinib is a second-generation, orally bioavailable small-molecule inhibitor of anaplastic lymphoma kinase (ALK), developed for tumours driven by ALK gene rearrangements, most notably ALK-rearranged NSCLC (PMID 24980964, 27738095, 28126333).
Gingival fibromatosis is a benign, typically hereditary or drug-induced (e.g., phenytoin, cyclosporine, calcium-channel blockers) overgrowth of gingival connective tissue. There is no established biological pathway connecting ALK receptor tyrosine kinase signalling to gingival fibrous overgrowth, and no fibroblast-proliferation or connective-tissue mechanism is referenced anywhere in the evidence supplied.
Consistent with this, the evidence pack's own rationale for this candidate states directly: there are no clinical trials, no literature, and no known mechanistic association between the ALK pathway and gingival fibromatosis — this is purely a TxGNN prediction score with no corroborating evidence of any kind.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Ceritinib is currently not marketed in Taiwan — 0 authorizations are on record, and the licenses array is empty, so no authorization number, product name, dosage form, or approved-indication text can be extracted from this evidence pack.
Cytotoxicity
Ceritinib is an antineoplastic agent (ALK/ROS1 tyrosine kinase inhibitor used in NSCLC per the literature evidence above), so this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (second-generation ALK tyrosine kinase inhibitor; not conventional cytotoxic chemotherapy) |
| Myelosuppression Risk | Not specifically reported in the supplied evidence; as a class, ALK inhibitors typically carry lower myelosuppressive risk than conventional cytotoxic chemotherapy — please refer to the package insert for haematological toxicity grading |
| Emetogenicity Classification | Moderate — GI toxicity is reported in the evidence (ASCEND-8 subgroup analysis, PMID 35344649, found reduced GI toxicity with a modified with-food dosing regimen, implying baseline GI toxicity is clinically relevant) |
| Monitoring Items | ECG/QTc interval (PMID 26008987, 29413968), liver function, GI symptoms (nausea, diarrhoea), thromboembolic events (PMID 39349372), and pulmonary/hypersensitivity symptoms (PMID 31280988 — case of diffuse infiltrative lung disease, pericarditis, and pleural effusion with ceritinib hypersensitivity) |
| Handling Protection | Not specified in the evidence pack. As an oral small-molecule targeted agent, follow institutional oral-oncolytic handling protocols pending confirmation from the TFDA package insert (see blocking data gap below) |
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data are all marked as data gaps in this evidence pack; the TFDA package insert has not yet been retrieved.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication, gingival fibromatosis, has no clinical trial or literature support and no plausible mechanistic link to ALK inhibition — it is a pure model-score artifact (L5, decision stage S0). None of the other 9 candidates in this batch fare better: the two with any literature (lung benign neoplasm, lung germ cell tumor, both L4) are explicitly flagged in their own rationale as ontology-driven mismatches (evidence concerns malignant NSCLC or glioblastoma/CNS metastasis, not the benign entities predicted), and the remaining 7 have no evidence at all.
To proceed, the following is needed:
- TFDA package insert retrieval and parsing for warnings/contraindications (blocking gap DG001)
- DrugBank MOA confirmation (DG002)
- If pursuing repurposing further, prioritize mechanistically plausible, evidence-searchable candidates (e.g., ALK-rearranged tumour subtypes) over the current top-ranked prediction
- No further development recommended for gingival fibromatosis or any of the other 9 predicted indications in this batch given the absence of supporting evidence and mechanistic plausibility
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.